PURPOSE: Breast cancer patients (BCP) are at risk of female sexual dysfunction (FSD). Our aim was to clarify the effects of treatment strategies, and steroid hormones levels on FSD. METHODS: We enrolled 136 BCP (46.9 ± 0.8 years), and 122 completed questionnaires. BCP were divided into four groups: 22 women with advanced breast cancer on neoadjuvant therapy (NAT), 48 on adjuvant therapy (AT), 30 taking hormonal therapy (HT) and 22 with metastatic cancer on first line chemotherapy (FLT). Fifty-eight healthy women (43 ± 2.8 years) were enrolled as controls. FSD was evaluated by FSFI, and sexual distress was assessed with FSDS-R. We have collected demographic data, laboratory values, and LH, FSH, total testosterone (T), and estradiol (E2) levels. RESULTS: BCP showed a prevalence of FSD of 69%, total FSFI score was 17. FSDS-R was 8.3. FSD had a prevalence of 72 % in NAT, 65% in AT, 77% in metastatic BCP under FLT, 67% in HT, compared with a prevalence of 20% in controls. BCP showed lower E2 than normal values, as well as T. LH and FSH were significantly elevated than normal values. Total FSFI score was positively correlated with T in 122 BCP, no significant correlation was found between E2 and FSFI. Significant differences were found between NAT and HT in lubrication, pain domains and total FSDS-R score, AT and HT in pain domain, AT and NAT in lubrication domain. CONCLUSIONS: BCP are at high risk of developing FSD both for treatment choice and hormonal status, but they have not sexually related personal distress.
PURPOSE:Breast cancerpatients (BCP) are at risk of female sexual dysfunction (FSD). Our aim was to clarify the effects of treatment strategies, and steroid hormones levels on FSD. METHODS: We enrolled 136 BCP (46.9 ± 0.8 years), and 122 completed questionnaires. BCP were divided into four groups: 22 women with advanced breast cancer on neoadjuvant therapy (NAT), 48 on adjuvant therapy (AT), 30 taking hormonal therapy (HT) and 22 with metastatic cancer on first line chemotherapy (FLT). Fifty-eight healthy women (43 ± 2.8 years) were enrolled as controls. FSD was evaluated by FSFI, and sexual distress was assessed with FSDS-R. We have collected demographic data, laboratory values, and LH, FSH, total testosterone (T), and estradiol (E2) levels. RESULTS:BCP showed a prevalence of FSD of 69%, total FSFI score was 17. FSDS-R was 8.3. FSD had a prevalence of 72 % in NAT, 65% in AT, 77% in metastatic BCP under FLT, 67% in HT, compared with a prevalence of 20% in controls. BCP showed lower E2 than normal values, as well as T. LH and FSH were significantly elevated than normal values. Total FSFI score was positively correlated with T in 122 BCP, no significant correlation was found between E2 and FSFI. Significant differences were found between NAT and HT in lubrication, pain domains and total FSDS-R score, AT and HT in pain domain, AT and NAT in lubrication domain. CONCLUSIONS:BCP are at high risk of developing FSD both for treatment choice and hormonal status, but they have not sexually related personal distress.
Entities:
Keywords:
Breast cancer; Chemotherapy; FSD; FSDS-R; FSFI; Testosterone
Authors: Justine J Speer; Bruce Hillenberg; Dennis P Sugrue; Charla Blacker; Cynthia L Kresge; Veronica B Decker; Dana Zakalik; David A Decker Journal: Breast J Date: 2005 Nov-Dec Impact factor: 2.431
Authors: Juliane Farthmann; A Hanjalic-Beck; J Veit; B Rautenberg; E Stickeler; T Erbes; M Földi; A Hasenburg Journal: Support Care Cancer Date: 2016-01-04 Impact factor: 3.603
Authors: Fiona G Li; Sarah Maheux-Lacroix; Rebecca Deans; Erin Nesbitt-Hawes; Aaron Budden; Kimberly Nguyen; Claire Y Lim; Sophia Song; Lalla McCormack; Stephen D Lyons; Eva Segelov; Jason A Abbott Journal: JAMA Date: 2021-10-12 Impact factor: 56.272
Authors: Jennifer Barsky Reese; Lauren A Zimmaro; Sarah McIlhenny; Kristen Sorice; Laura S Porter; Alexandra K Zaleta; Mary B Daly; Beth Cribb; Jessica R Gorman Journal: Front Psychol Date: 2022-04-06